Stocks trading under $10 rarely come with the potential for life-changing gains, especially in today’s cautious market. In most sectors, that kind of upside is almost unheard of. Some biotech stocks, however, are an exception. When encouraging clinical data and regulatory milestones align, a single breakthrough can rapidly reprice a biotech stock. That is precisely why Wall Street expects this under-$10 biotech company to skyrocket by as much as 404% in 2026. Let’s find out why.
